ACMT Position Statement: Allow Optimal Treatment for Healthcare Professionals with Opioid Use Disorder
J Med Toxicol
.
2022 Jan;18(1):71-73.
doi: 10.1007/s13181-021-00861-4.
Epub 2021 Oct 25.
Authors
Ryan T Marino
1
,
Meghan Spyres
2
3
,
Timothy J Wiegand
4
,
Kavita M Babu
5
,
Andrew Stolbach
6
Affiliations
1
Departments of Emergency Medicine & Psychiatry, Case Western Reserve University School of Medicine, Cleveland, OH, 44106, USA.
2
Department of Medical Toxicology, Banner University Medical Center Phoenix, Phoenix, AZ, USA.
3
University of Arizona College of Medicine Phoenix, Phoenix, AZ, USA.
4
University of Rochester Medical Center, Rochester, NY, USA.
5
Division of Medical Toxicology, Department of Emergency Medicine, University of Massachusetts Medical School, Worcester, MA, USA.
6
Johns Hopkins University School of Medicine, Baltimore, MD, USA. positionstatements@acmt.net.
PMID:
34697778
PMCID:
PMC8758878
DOI:
10.1007/s13181-021-00861-4
No abstract available
Keywords:
Buprenorphine; Health care professionals; Impairment; Opioid use disorder; Physicians.
MeSH terms
Delivery of Health Care
Health Personnel
Humans
Opioid-Related Disorders* / therapy